Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovarian malignancy.

J M Niloff1

  • 1Division of Gynecologic Oncology, Beth Israel Hospital, Boston, MA 02215.

Current Opinion in Obstetrics & Gynecology
|February 1, 1991
PubMed
Summary

Despite advances in ovarian cancer management, prognosis remains poor. However, CA-125 aids in predicting chemotherapy response and survival, guiding treatment for advanced stages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and predictors of cervical dysplasia in patients with minimally abnormal pap smears.

Journal of lower genital tract disease·2015
Same author

Identification of cervical intraepithelial neoplasia (CIN) using UV-excited fluorescence and diffuse-reflectance tissue spectroscopy.

Lasers in surgery and medicine·2001
Same author

Early discharge after abdominal surgery: experience on a gynecologic oncology service.

Gynecologic oncology·1999
Same author

Outpatient minilaparotomy for ovarian cysts.

The Journal of reproductive medicine·1999
Same author

Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears.

Obstetrics and gynecology·1998
Same author

Cancer of the uterine cervix.

The New England journal of medicine·1996

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Biomarkers

Background:

  • Ovarian cancer prognosis remains poor despite recent management advances.
  • Current early detection methods, including sonography and tumor markers, have been unsuccessful.
  • The tumor marker CA-125 is valuable for assessing chemotherapy response and predicting survival.

Purpose of the Study:

  • To review current management strategies for ovarian cancer.
  • To highlight the role of CA-125 in treatment response and survival prediction.
  • To discuss the efficacy of carboplatin and Taxol in ovarian cancer treatment.

Main Methods:

  • Review of recent literature on ovarian cancer management.
  • Analysis of the utility of CA-125 in predicting treatment outcomes.
  • Evaluation of chemotherapy agents like carboplatin and Taxol.
  • Assessment of the role of second-look surgery and immunotherapy.

Main Results:

  • Well-differentiated early-stage ovarian cancers have excellent survival without adjuvant therapy.
  • Poorly differentiated stage I and II tumors have a significant failure rate, necessitating treatment.
  • Carboplatin is a preferred platinum analogue due to its toxicity profile.
  • Taxol shows promise as a new active agent, potentially effective in combination with platinum.
  • Routine second-look surgery is no longer recommended.
  • Tumor heterogeneity may limit the effectiveness of immunotherapies targeting cell surface antigens.

Conclusions:

  • Treatment decisions for ovarian cancer should be guided by differentiation and stage.
  • Carboplatin and Taxol represent important therapeutic options.
  • The role of CA-125 in monitoring treatment response and survival is critical.
  • Future research should consider tumor heterogeneity in treatment strategies, particularly for immunotherapy.

Related Experiment Videos